000291102 001__ 291102
000291102 005__ 20241029134413.0
000291102 0247_ $$2doi$$a10.3390/cancers16111955
000291102 0247_ $$2pmid$$apmid:38893076
000291102 0247_ $$2pmc$$apmc:PMC11171022
000291102 037__ $$aDKFZ-2024-01307
000291102 041__ $$aEnglish
000291102 082__ $$a610
000291102 1001_ $$00000-0003-4446-8257$$aAdolph, Jonas E$$b0
000291102 245__ $$aRadiotherapy for Recurrent Medulloblastoma in Children and Adolescents: Survival after Re-Irradiation and First-Time Irradiation.
000291102 260__ $$aBasel$$bMDPI$$c2024
000291102 3367_ $$2DRIVER$$aarticle
000291102 3367_ $$2DataCite$$aOutput Types/Journal article
000291102 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1718873514_15767
000291102 3367_ $$2BibTeX$$aARTICLE
000291102 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291102 3367_ $$00$$2EndNote$$aJournal Article
000291102 520__ $$aRadiotherapy (RT) involving craniospinal irradiation (CSI) is important in the initial treatment of medulloblastoma. At recurrence, the re-irradiation options are limited and associated with severe side-effects.For pre-irradiated patients, patients with re-irradiation (RT2) were matched by sex, histology, time to recurrence, disease status and treatment at recurrence to patients without RT2.A total of 42 pre-irradiated patients with RT2 were matched to 42 pre-irradiated controls without RT2. RT2 improved the median PFS [21.0 (CI: 15.7-28.7) vs. 12.0 (CI: 8.1-21.0) months] and OS [31.5 (CI: 27.6-64.8) vs. 20.0 (CI: 14.0-36.7) months]. Concerning long-term survival after ten years, RT2 only lead to small improvements in OS [8% (CI: 1.4-45.3) vs. 0%]. RT2 improved survival most without (re)-resection [PFS: 17.5 (CI: 9.7-41.5) vs. 8.0 (CI: 6.6-12.2)/OS: 31.5 (CI: 27.6-NA) vs. 13.3 (CI: 8.1-20.1) months]. In the RT-naïve patients, CSI at recurrence improved their median PFS [25.0 (CI: 16.8-60.6) vs. 6.6 (CI: 1.5-NA) months] and OS [40.2 (CI: 18.7-NA) vs. 12.4 (CI: 4.4-NA) months].RT2 could improve the median survival in a matched cohort but offered little benefit regarding long-term survival. In RT-naïve patients, CSI greatly improved their median and long-term survival.
000291102 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000291102 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291102 650_7 $$2Other$$amedulloblastoma
000291102 650_7 $$2Other$$aradiotherapy
000291102 650_7 $$2Other$$are-irradiation
000291102 650_7 $$2Other$$arecurrence
000291102 650_7 $$2Other$$aresection
000291102 7001_ $$00000-0001-5714-007X$$aFleischhack, Gudrun$$b1
000291102 7001_ $$aTschirner, Sebastian$$b2
000291102 7001_ $$aRink, Lydia$$b3
000291102 7001_ $$aDittes, Christine$$b4
000291102 7001_ $$aMikasch, Ruth$$b5
000291102 7001_ $$aDammann, Philipp$$b6
000291102 7001_ $$00000-0003-3302-2719$$aMynarek, Martin$$b7
000291102 7001_ $$aObrecht-Sturm, Denise$$b8
000291102 7001_ $$aRutkowski, Stefan$$b9
000291102 7001_ $$00000-0001-5849-8671$$aBison, Brigitte$$b10
000291102 7001_ $$aWarmuth-Metz, Monika$$b11
000291102 7001_ $$aPietsch, Torsten$$b12
000291102 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b13$$udkfz
000291102 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b14$$udkfz
000291102 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b15$$udkfz
000291102 7001_ $$aKortmann, Rolf-Dieter$$b16
000291102 7001_ $$00000-0001-6141-2170$$aDietzsch, Stefan$$b17
000291102 7001_ $$00000-0003-2274-2008$$aTimmermann, Beate$$b18
000291102 7001_ $$00000-0001-8791-9914$$aTippelt, Stephan$$b19
000291102 7001_ $$aHIT-Network, German GPOH$$b20$$eCollaboration Author
000291102 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers16111955$$gVol. 16, no. 11, p. 1955 -$$n11$$p1955$$tCancers$$v16$$x2072-6694$$y2024
000291102 8564_ $$uhttps://inrepo02.dkfz.de/record/291102/files/cancers-16-01955.pdf
000291102 8564_ $$uhttps://inrepo02.dkfz.de/record/291102/files/cancers-16-01955.pdf?subformat=pdfa$$xpdfa
000291102 909CO $$ooai:inrepo02.dkfz.de:291102$$pVDB
000291102 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000291102 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000291102 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b15$$kDKFZ
000291102 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000291102 9141_ $$y2024
000291102 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2022$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-07-31T16:07:06Z
000291102 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-07-31T16:07:06Z
000291102 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-07-31T16:07:06Z
000291102 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2023-07-31T16:07:06Z
000291102 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2022$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-26
000291102 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-26
000291102 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000291102 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x1
000291102 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000291102 980__ $$ajournal
000291102 980__ $$aVDB
000291102 980__ $$aI:(DE-He78)B062-20160331
000291102 980__ $$aI:(DE-He78)B310-20160331
000291102 980__ $$aI:(DE-He78)HD01-20160331
000291102 980__ $$aUNRESTRICTED